- Home
- NRC vs CLLS Comparison
NRC vs CLLS Comparison
Compare NRC & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRC
- CLLS
- Stock Information
- Founded
- NRC 1981
- CLLS 1999
- Country
- NRC United States
- CLLS France
- Employees
- NRC N/A
- CLLS N/A
- Industry
- NRC Biotechnology: Commercial Physical & Biological Resarch
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- NRC Health Care
- CLLS Health Care
- Exchange
- NRC Nasdaq
- CLLS Nasdaq
- Market Cap
- NRC 278.8M
- CLLS 299.0M
- IPO Year
- NRC N/A
- CLLS 2007
- Fundamental
- Price
- NRC $16.11
- CLLS $4.11
- Analyst Decision
- NRC
- CLLS Buy
- Analyst Count
- NRC 0
- CLLS 1
- Target Price
- NRC N/A
- CLLS $8.00
- AVG Volume (30 Days)
- NRC 102.3K
- CLLS 78.0K
- Earning Date
- NRC 10-27-2025
- CLLS 11-07-2025
- Dividend Yield
- NRC 4.20%
- CLLS N/A
- EPS Growth
- NRC N/A
- CLLS N/A
- EPS
- NRC 0.71
- CLLS N/A
- Revenue
- NRC $139,102,000.00
- CLLS $82,551,000.00
- Revenue This Year
- NRC N/A
- CLLS N/A
- Revenue Next Year
- NRC N/A
- CLLS $58.00
- P/E Ratio
- NRC $21.45
- CLLS N/A
- Revenue Growth
- NRC N/A
- CLLS 129.04
- 52 Week Low
- NRC $9.76
- CLLS $1.10
- 52 Week High
- NRC $20.11
- CLLS $5.48
- Technical
- Relative Strength Index (RSI)
- NRC 73.66
- CLLS 63.84
- Support Level
- NRC $14.75
- CLLS $3.49
- Resistance Level
- NRC $14.18
- CLLS $3.86
- Average True Range (ATR)
- NRC 0.74
- CLLS 0.22
- MACD
- NRC 0.30
- CLLS 0.06
- Stochastic Oscillator
- NRC 95.77
- CLLS 88.01
About NRC National Research Corporation (Delaware)
National Research Corp is a provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers, and other healthcare organizations. Its portfolio of solutions represents a set of capabilities that individually and collectively provide value to clients. It operates in the United States and Canada, of which key revenue is derived from the United States.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.